{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T01:58:12Z","timestamp":1775008692107,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,8,29]],"date-time":"2021-08-29T00:00:00Z","timestamp":1630195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,29]],"date-time":"2021-08-29T00:00:00Z","timestamp":1630195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s10072-021-05579-3","type":"journal-article","created":{"date-parts":[[2021,8,29]],"date-time":"2021-08-29T09:02:25Z","timestamp":1630227745000},"page":"1755-1759","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Serum levels of lipocalin-2 in patients with Parkinson\u2019s disease"],"prefix":"10.1007","volume":"43","author":[{"given":"Mi","family":"Xiong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8481-0363","authenticated-orcid":false,"given":"You-Dong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,29]]},"reference":[{"issue":"9996","key":"5579_CR1","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/s0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE (2015) Parkinson\u2019s disease. Lancet (London, England) 386(9996):896\u2013912. https:\/\/doi.org\/10.1016\/s0140-6736(14)61393-3","journal-title":"Lancet (London, England)"},{"issue":"12","key":"5579_CR2","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord 30(12):1591\u20131601. https:\/\/doi.org\/10.1002\/mds.26424","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"5579_CR3","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1016\/j.parkreldis.2015.09.004","volume":"22","author":"RF Pfeiffer","year":"2016","unstructured":"Pfeiffer RF (2016) Non-motor symptoms in Parkinson\u2019s disease. Parkinsonism Relat Disord 22(Suppl 1):S119-122. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.09.004","journal-title":"Parkinsonism Relat Disord"},{"issue":"s1","key":"5579_CR4","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.3233\/jpd-179001","volume":"7","author":"H Braak","year":"2017","unstructured":"Braak H, Del Tredici K (2017) Neuropathological staging of brain pathology in sporadic Parkinson\u2019s disease: separating the wheat from the chaff. J Parkinsons Dis 7(s1):S71\u2013S85. https:\/\/doi.org\/10.3233\/jpd-179001","journal-title":"J Parkinsons Dis"},{"issue":"3","key":"5579_CR5","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.nbd.2009.11.004","volume":"37","author":"MG Tansey","year":"2010","unstructured":"Tansey MG, Goldberg MS (2010) Neuroinflammation in Parkinson\u2019s disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37(3):510\u2013518. https:\/\/doi.org\/10.1016\/j.nbd.2009.11.004","journal-title":"Neurobiol Dis"},{"key":"5579_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28075","author":"EC Hirsch","year":"2020","unstructured":"Hirsch EC, Standaert DG (2020) Ten unsolved questions about neuroinflammation in Parkinson\u2019s disease. Mov Disord. https:\/\/doi.org\/10.1002\/mds.28075","journal-title":"Mov Disord"},{"key":"5579_CR7","doi-asserted-by":"publisher","first-page":"4784268","DOI":"10.1155\/2018\/4784268","volume":"2018","author":"G Gelders","year":"2018","unstructured":"Gelders G, Baekelandt V, Van der Perren A (2018) Linking neuroinflammation and neurodegeneration in Parkinson\u2019s disease. J Immunol Res 2018:4784268. https:\/\/doi.org\/10.1155\/2018\/4784268","journal-title":"J Immunol Res"},{"issue":"5","key":"5579_CR8","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.tem.2017.01.003","volume":"28","author":"AR Moschen","year":"2017","unstructured":"Moschen AR, Adolph TE, Gerner RR, Wieser V, Tilg H (2017) Lipocalin-2: a master mediator of intestinal and metabolic inflammation. Trends Endocrinol Metab 28(5):388\u2013397. https:\/\/doi.org\/10.1016\/j.tem.2017.01.003","journal-title":"Trends Endocrinol Metab"},{"key":"5579_CR9","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.pneurobio.2015.06.005","volume":"131","author":"AC Ferreira","year":"2015","unstructured":"Ferreira AC, D\u00e1 Mesquita S, Sousa JC, Correia-Neves M, Sousa N, Palha JA, Marques F (2015) From the periphery to the brain: Lipocalin-2, a friend or foe? Prog Neurobiol 131:120\u2013136. https:\/\/doi.org\/10.1016\/j.pneurobio.2015.06.005","journal-title":"Prog Neurobiol"},{"issue":"20","key":"5579_CR10","doi-asserted-by":"publisher","first-page":"5608","DOI":"10.1523\/jneurosci.4261-15.2016","volume":"36","author":"BW Kim","year":"2016","unstructured":"Kim BW, Jeong KH, Kim JH, Jin M, Kim JH, Lee MG, Choi DK, Won SY, McLean C, Jeon MT, Lee HW, Kim SR, Suk K (2016) Pathogenic upregulation of glial lipocalin-2 in the Parkinsonian dopaminergic system. J Neurosci 36(20):5608\u20135622. https:\/\/doi.org\/10.1523\/jneurosci.4261-15.2016","journal-title":"J Neurosci"},{"issue":"1","key":"5579_CR11","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12974-017-0935-1","volume":"14","author":"LN Eidson","year":"2017","unstructured":"Eidson LN, Kannarkat GT, Barnum CJ, Chang J, Chung J, Caspell-Garcia C, Taylor P, Mollenhauer B, Schlossmacher MG, Ereshefsky L, Yen M, Kopil C, Frasier M, Marek K, Hertzberg VS, Tansey MG (2017) Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson\u2019s disease. J Neuroinflammation 14(1):164. https:\/\/doi.org\/10.1186\/s12974-017-0935-1","journal-title":"J Neuroinflammation"},{"issue":"1","key":"5579_CR12","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.dadm.2019.07.004","volume":"11","author":"E Eruysal","year":"2019","unstructured":"Eruysal E, Ravdin L, Kamel H, Iadecola C, Ishii M, Zetterberg H (2019) Plasma lipocalin-2 levels in the preclinical stage of Alzheimer\u2019s disease. Alzheimers Dement 11(1):646\u2013653. https:\/\/doi.org\/10.1016\/j.dadm.2019.07.004","journal-title":"Alzheimers Dement"},{"issue":"1\u20132","key":"5579_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jns.2011.03.023","volume":"305","author":"J Choi","year":"2011","unstructured":"Choi J, Lee H-W, Suk K (2011) Increased plasma levels of lipocalin 2 in mild cognitive impairment. J Neurol Sci 305(1\u20132):28\u201333. https:\/\/doi.org\/10.1016\/j.jns.2011.03.023","journal-title":"J Neurol Sci"},{"issue":"1","key":"5579_CR14","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41467-020-14373-2","volume":"11","author":"F Llorens","year":"2020","unstructured":"Llorens F, Hermann P, Villar-Pique A, Diaz-Lucena D, Nagga K, Hansson O, Santana I, Schmitz M, Schmidt C, Varges D, Goebel S, Dumurgier J, Zetterberg H, Blennow K, Paquet C, Baldeiras I, Ferrer I, Zerr I (2020) Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia. Nat Commun 11(1):619. https:\/\/doi.org\/10.1038\/s41467-020-14373-2","journal-title":"Nat Commun"},{"issue":"19","key":"5579_CR15","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1212\/WNL.0b013e3181fc29c9","volume":"75","author":"JC Dalrymple-Alford","year":"2010","unstructured":"Dalrymple-Alford JC, MacAskill MR, Nakas CT, Livingston L, Graham C, Crucian GP, Melzer TR, Kirwan J, Keenan R, Wells S, Porter RJ, Watts R, Anderson TJ (2010) The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 75(19):1717\u20131725. https:\/\/doi.org\/10.1212\/WNL.0b013e3181fc29c9","journal-title":"Neurology"},{"issue":"3","key":"5579_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181\u2013184. https:\/\/doi.org\/10.1136\/jnnp.55.3.181","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5579_CR17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/978-3-7091-6301-6_19","volume":"60","author":"T Nagatsu","year":"2000","unstructured":"Nagatsu T, Mogi M, Ichinose H, Togari A (2000) Changes in cytokines and neurotrophins in Parkinson\u2019s disease. J Neural Transm Suppl 60:277\u2013290. https:\/\/doi.org\/10.1007\/978-3-7091-6301-6_19","journal-title":"J Neural Transm Suppl"},{"issue":"6301","key":"5579_CR18","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1126\/science.aag2590","volume":"353","author":"RM Ransohoff","year":"2016","unstructured":"Ransohoff RM (2016) How neuroinflammation contributes to neurodegeneration. Science (New York, NY) 353(6301):777\u2013783. https:\/\/doi.org\/10.1126\/science.aag2590","journal-title":"Science (New York, NY)"},{"key":"5579_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev-nutr-071816-064559","volume":"37","author":"X Xiao","year":"2017","unstructured":"Xiao X, Yeoh BS, Vijay-Kumar M (2017) Lipocalin 2: an emerging player in iron homeostasis and inflammation. Annu Rev Nutr 37:103\u2013130. https:\/\/doi.org\/10.1146\/annurev-nutr-071816-064559","journal-title":"Annu Rev Nutr"},{"issue":"4","key":"5579_CR20","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/mds.27275","volume":"33","author":"C Moreau","year":"2018","unstructured":"Moreau C, Duce JA, Rascol O, Devedjian JC, Berg D, Dexter D, Cabantchik ZI, Bush AI, Devos D, Group F-Is (2018) Iron as a therapeutic target for Parkinson\u2019s disease. Mov Disord 33(4):568\u2013574. https:\/\/doi.org\/10.1002\/mds.27275","journal-title":"Mov Disord"},{"issue":"10","key":"5579_CR21","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/s1474-4422(14)70117-6","volume":"13","author":"RJ Ward","year":"2014","unstructured":"Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L (2014) The role of iron in brain ageing and neurodegenerative disorders. The Lancet Neurology 13(10):1045\u20131060. https:\/\/doi.org\/10.1016\/s1474-4422(14)70117-6","journal-title":"The Lancet Neurology"},{"issue":"12","key":"5579_CR22","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1177\/1352458515624560","volume":"22","author":"M Khalil","year":"2016","unstructured":"Khalil M, Renner A, Langkammer C, Enzinger C, Ropele S, Stojakovic T, Scharnagl H, Bachmaier G, Pichler A, Archelos JJ, Fuchs S, Seifert-Held T, Fazekas F (2016) Cerebrospinal fluid lipocalin 2 in patients with clinically isolated syndromes and early multiple sclerosis. Mult Scler J 22(12):1560\u20131568. https:\/\/doi.org\/10.1177\/1352458515624560","journal-title":"Mult Scler J"},{"issue":"7","key":"5579_CR23","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/glia.22342","volume":"60","author":"JL Berard","year":"2012","unstructured":"Berard JL, Zarruk JG, Arbour N, Prat A, Yong VW, Jacques FH, Akira S, David S (2012) Lipocalin 2 is a novel immune mediator of experimental autoimmune encephalomyelitis pathogenesis and is modulated in multiple sclerosis. Glia 60(7):1145\u20131159. https:\/\/doi.org\/10.1002\/glia.22342","journal-title":"Glia"},{"key":"5579_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fncel.2012.00033","volume":"6","author":"F Marques","year":"2012","unstructured":"Marques F, Mesquita SD, Sousa JC, Coppola G, Gao F, Geschwind DH, Columba-Cabezas S, Aloisi F, Degn M, Cerqueira JJ, Sousa N, Correia-Neves M, Palha JA (2012) Lipocalin 2 is present in the EAE brain and is modulated by natalizumab. Front Cell Neurosci 6:33. https:\/\/doi.org\/10.3389\/fncel.2012.00033","journal-title":"Front Cell Neurosci"},{"key":"5579_CR25","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3389\/fncel.2013.00122","volume":"7","author":"AC Ferreira","year":"2013","unstructured":"Ferreira AC, Pinto V, Da Mesquita S, Novais A, Sousa JC, Correia-Neves M, Sousa N, Palha JA, Marques F (2013) Lipocalin-2 is involved in emotional behaviors and cognitive function. Front Cell Neurosci 7:122. https:\/\/doi.org\/10.3389\/fncel.2013.00122","journal-title":"Front Cell Neurosci"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05579-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-021-05579-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05579-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T11:36:41Z","timestamp":1645443401000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-021-05579-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,29]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["5579"],"URL":"https:\/\/doi.org\/10.1007\/s10072-021-05579-3","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,29]]},"assertion":[{"value":"20 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our research was\u00a0approved by the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent of all participants was obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed\u00a0consent"}},{"value":"The authors declare no competting interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}